Patients suffering from iron overload can experience serious complications. In such patients,
various organs, such as endocrine glands and liver, can be damaged. Although iron is a …

Beta-thalassaemia causes defective haemoglobin synthesis leading to ineffective
erythropoiesis, chronic haemolytic anaemia, and subsequent clinical complications. Blood …

The prevalence rate of thalassemia, which is endemic in Southeast Asia, the Middle East,
and the Mediterranean, exceeds 100,000 live births per year. There are many genetic …

Transfusional iron overload is a major target in the care of patients with transfusion-
dependent thalassemia (TDT) and other refractory anemias. Iron accumulates in the liver …

Neurologic complications are a major cause of morbidity and mortality in sickle cell disease
(SCD). In children with sickle cell anemia, routine use of transcranial Doppler screening …

Deferiprone (L1) was originally designed, synthesised and screened in vitro and in vivo in
1981 by Kontoghiorghes GJ following his discovery of the novel alpha-ketohydroxypyridine …

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron
concentrations (LIC), although some patients may require intensive chelation for a limited …

Purpose Iron chelation has improved survival and quality of life of patients with thalassemia
major. there are currently 3 commercially available iron-chelating drugs with different …

This review outlines the effectiveness and safety of 10 different regimens for controlling iron
overloading in thalassaemia major (TM). For each treatment, the strength of the evidence …

The aim of this study is the evaluation of the safety and the efficacy of long-term combination
therapy deferasirox plus desferrioxamine and deferasirox plus deferiprone in a large group …